ArticleChina CDC weekly2024
Incidence and Mortality of Cancers in Female Genital Organs - China, 2022.
Article in China CDC weekly, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Differential diagnostic value of PAX1 and JAM3 methylation for cervical intraepithelial neoplasia between premenopausal and postmenopausal women: a retrospective clinical study in China.Annals of medicine · 2026Article
- Incidence of Gynecological Cancers Is Rising in Northern Iran: A Population-Based, Serial Cross-Sectional Joinpoint Regression Study.Health science reports · 2026Article
- HPV genotype distribution and cervical lesions in colposcopy-referred women in Western China: a cross-sectional study.BMC cancer · 2026Article
- Article
- Endometrial cancer mortality and its trends in China from 2004-2021.BMC cancer · 2026Article
- The quality and reliability of endometrial cancer-related videos on social short video platforms: a cross-sectional study.BMC women's health · 2026Article
- Diagnostic performance and interobserver agreement of O-RADS US v2022 and its combination with serum biomarkers in surgically treated epithelial ovarian-adnexal masses.Frontiers in medicine · 2026Article
- Cervical cancer burden and trends in China, 2000-2020: Asia-Pacific international comparisons and insights for elimination goals.Cancer biology & medicine · 2025Article
- Participation, knowledge, and attitudes toward cervical cancer screening among migrant Burmese women on China-Myanmar border: a cross-sectional study.Preventive medicine reports · 2025Article
- Association between knowledge of cervical cancer prevention and screening behaviors among women aged 20 to 49 years: a cross-sectional study in six provinces, China.BMC public health · 2025Article
- Identification of a Biomarker Panel in Extracellular Vesicles Derived From Non-Small Cell Lung Cancer (NSCLC) Through Proteomic Analysis and Machine Learning.Journal of extracellular vesicles · 2025Article
- Association Between High-Risk Human Papillomavirus Infection and Cervical Cytology in Health Check-Up Women - 23 PLADs, China, 2023.China CDC weekly · 2025Article
- Epidemiological study of HPV infection in 24,588 rural women in Luonan, China.Gynecologic oncology reports · 2025Article
- The impact of vaccine access difficulties on HPV vaccine intention and uptake among female university students in China.International journal for equity in health · 2025Article
- Integrative multi-omics and machine learning approach reveals tumor microenvironment-associated prognostic biomarkers in ovarian cancer.Translational cancer research · 2024Article
- Assessment ofFrontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study presented the incidence and mortality rates of cancers affecting the female genital organs in China, along with their trends spanning from 2010 to 2018. Methods: 700 population-based cancer registries provided relevant cancer incidence and mortality data for the year 2018. Among these, 106 registries had continuous monitoring data suitable for trend analysis from 2010 to 2018. We focused specifically on cancers affecting female genital organs (ICD10=C51-C54, C56) and projected their incidences and mortalities in China for 2022 based on data from 2018 and the trends observed from 2010 to 2018. Age-standardized incidence rate (ASIR) and mortality rate (ASMR) were calculated using Segi's world standard population. Results: In 2022, there were an estimated 296,300 new cases and 104,900 deaths from female cancers in China. ASIRs for vulva (C51), vagina (C52), cervix uteri (C53), corpus uteri (C54), and ovary (C56) were 0.32, 0.23, 13.83, 6.84, and 5.68 per 100,000 population. ASIRs for corpus uteri and ovary cancers were higher in urban areas. ASMRs for vulva, vagina, cervix, corpus uteri, and ovary cancers were 0.14, 0.08, 4.54, 1.05, and 2.64 per 100,000 population, respectively. ASMR for ovarian cancer was higher in urban areas. ASIRs and ASMRs for most female genital organ cancers increased from 2010 to 2018, although the rate of increase for vulvar and cervical cancers in rural areas has slowed recently. Conclusions: Tailored cancer prevention and control programs specific to each region are necessary to address the growing disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.